ABUS

Arbutus BiopharmaB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

25%

Probability

Target price

$7.35

Analysis reference price unavailable

Analysis 2026-03-26 · RankAlpha Sentiment AI

Most likely

Base case

50%

Probability

Target price

$5.68

Analysis reference price unavailable

Analysis 2026-03-26 · RankAlpha Sentiment AI

B-

Bear case

25%

Probability

Target price

$3.00

Analysis reference price unavailable

Analysis 2026-03-26 · RankAlpha Sentiment AI

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-03-26

AI commentary

Recent corporate update and Q4/2025 results refreshed focus on cash runway and corporate strategy; coverage tone is cautiously constructive given limited near-term program catalysts and a modest analyst target range [#8-K-2026-03-23] [#PR-undated]. Market commentary emphasizes financing/partnering as the pivotal near-term call [#SERP-3].

RankAlpha Sentiment AI - 2026-03-26

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-06-24catalystNext quarterly results / corporate update (Q1 2026)High impact

Market will re-price on Q1 2026 operational/financial detail and management commentary following the Q4/2025 release; investors should watch cash/runway commentary and program updates referenced in the March 23, 2026 corporate update [#8-K-2026-03-23].

2027-03-26catalystBalance-sheet-driven financing or partnering decision within 12 monthsHigh impact

Arbutus reported cash, cash equivalents and marketable securities of ~$91.5M at year-end 2025 per the March 23, 2026 release; that runway math makes a financing, partnership, or explicit runway-extension plan the likely company action within the next year, which would materially affect valuation [#8-K-2026-03-23] [#PR-undated].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-03-26 • Updated nightlySource: Internal modelMethodology